[{"type": "title", "data": "OB Postpartum VTE Thromboprophylaxis (Module)"}, {"type": "category", "data": "Admit/Transfer/Discharge"}, {"type": "note", "data": "Refer to Society of Obstetricians and Gynaecologists of Canada (SOGC) Clinical Practice Guideline Venous Thromboembolism and Antithrombotic Therapy in Pregnancy", "value": ""}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "Review attached VTE decision tree to determine risk category for patient before completing orders", "value": ""}, {"type": "note", "data": "VTE RISK IS LOW", "value": ""}, {"type": "order", "data": "Ambulate", "value": ""}, {"type": "sentence", "data": "Mobilize early and avoid dehydration"}, {"type": "note", "data": "VTE RISK IS MODERATE OR HIGH WITHOUT CONTRAINDICATION TO ANTICOAGULANTS", "value": ""}, {"type": "note", "data": "Pharmacologic Thromboprophylaxis CONTRAINDICATED if  \n- Active bleeding of clinical significance requiring intervention  \n- High risk of serious bleeding or bleeding into a critical site (e.g. intracranial, intraspinal, pericardial, intraocular, retroperitoneal, intra-articular)  \n- Known major bleeding disorder or acquired coagulopathy (consider Hematology consult)  \n- Platelet count LESS than 50 X 10^9/L (consider Hematology consult)\n- If history of Heparin-Induced Thrombocytopenia (HIT), DO NOT give LMWH or heparin. Consult Hematology / Internal Medicine for alternate anticoagulation\n- Patient already receiving therapeutic anticoagulation \n- Hypersensitivity to low molecular weight heparin (LMWH) [enoxaparin] ", "value": ""}, {"type": "note", "data": "Pharmacologic Thromboprophylaxis should be HELD UNTIL FURTHER ASSESSMENT in clinical setting if  - Blood patch is planned or being considered, do not give LMWH (enoxaparin)  - PPH with active bleeding and medically unstable: delay LMWH until stable  - If intra-op \"oozing\", ordering physician may delay the initial dose", "value": ""}, {"type": "note", "data": "DO NOT administer low molecular weight heparin (LMWH) (enoxaparin) within 4 hours of epidural catheter removal", "value": ""}, {"type": "order", "data": "VTE Prophylaxis Contraindication", "value": ""}, {"type": "sentence", "data": "Contraindication: Active Bleeding Requiring Intervention"}, {"type": "sentence", "data": "Contraindication: Risk of Serious Bleed in Critical Site"}, {"type": "sentence", "data": "Contraindication: Known Major Bleed Disorder/Coagulopathy"}, {"type": "sentence", "data": "Contraindication: Platelet Count Less Than 50 x 10^9/L"}, {"type": "sentence", "data": "Contraindication: Hx of Heparin-Induced Thrombocytopenia, DO NOT give LMWH or heparin"}, {"type": "sentence", "data": "Contraindication: Receiving Therapeutic Anticoagulant"}, {"type": "note", "data": "Pharmacologic Prophylaxis:", "value": ""}, {"type": "note", "data": "BID dosing is contraindicated if epidural left in situ, consult anesthesia", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "40 mg, subcutaneous, q24h, drug form: syringe-inj"}, {"type": "sentence", "data": "40 mg, subcutaneous, q12h, drug form: syringe-inj"}, {"type": "sentence", "data": "60 mg, subcutaneous, q12h, drug form: syringe-inj"}, {"type": "note", "data": "If patient has abnormal renal function consult pharmacy or internal medicine prior to next dose of enoxaparin", "value": ""}, {"type": "order", "data": "Do not Remove Epidural Catheter", "value": ""}, {"type": "sentence", "data": "Within 12 hours of dose if epidural catheter in situ when LMWH (enoxaparin or dalteparin)  is administered"}, {"type": "order", "data": "Conditional Order - Ongoing", "value": ""}, {"type": "sentence", "data": "If/when planned blood patch, active bleeding or medically unstable PPH, then HOLD LMWH (enoxaparin or dalteparin)"}, {"type": "order", "data": "zzPatient Education", "value": ""}, {"type": "sentence", "data": "Women at moderate or high risk should be advised of the signs and symptoms of venous thromboembolism"}, {"type": "order", "data": "Conditional Order - Ongoing", "value": ""}, {"type": "sentence", "data": "If/when protamine sulfate needed for reversal, then contact Provider STAT for order (Refer to Parenteral Drug Therapy Manual for Protamine dosing)"}, {"type": "note", "data": "If ongoing and persistent risk factors for VTE exist", "value": ""}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "Educate patients for self administration of pharmacologic thromboprophylaxis, prevention of VTE and signs / symptoms of abnormal bleeding"}, {"type": "note", "data": "VTE RISK IS MODERATE WITH CONTRAINDICATION TO ANTICOAGULANTS or HIGH RISK", "value": ""}, {"type": "note", "data": "Mechanical Prophylaxis (SCD) CONTRAINDICATED if  - Acute stroke with immobility (unable to walk independently to the toilet)  - Peripheral vascular disease with absent pedal pulses  - Severe peripheral neuropathy  - Skin breakdown, ulcers, gangrene, cellulitis or dermatitis  - Skin grafting within last 3 months  - Allergy to stocking or compression cuff materials  - Unable to size or apply properly due to deformity, recent surgery or trauma", "value": ""}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No mechanical prophylaxis because of contraindications"}, {"type": "order", "data": "Patient Education", "value": ""}, {"type": "sentence", "data": "Women at moderate or high risk should be advised of the signs and symptoms of venous thromboembolism"}, {"type": "order", "data": "Apply Full Leg SCDs", "value": ""}, {"type": "sentence", "data": "Apply by 1 hour post-delivery to lower limb(s) continuously or until patient is fully ambulatory.  Interrupt for skin care, assessments, ambulation only"}, {"type": "order", "data": "Apply Below the Knee SCDs", "value": ""}, {"type": "sentence", "data": "Apply by 1 hour post-delivery to lower limb(s) continuously or until patient is fully ambulatory.  Interrupt for skin care, assessments, ambulation only"}]
